Study of CKD-215 and D215 in Adults With BRCA-mutated Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Chong Kun Dang Pharmaceutical
Chong Kun Dang Pharmaceutical
Regor Pharmaceuticals Inc.
University of Washington
University of Kentucky
Roswell Park Cancer Institute
Second Affiliated Hospital, School of Medicine, Zhejiang University
GlaxoSmithKline
Georgetown University
Peking University Third Hospital
WestVac Biopharma Co., Ltd.
On Target Laboratories, LLC
University of California, Irvine
Qilu Pharmaceutical Co., Ltd.
The First Affiliated Hospital of Soochow University
Convalife (Shanghai) Co., Ltd.
Cancer Research UK
Kaiser Permanente
Ellele Health
University of Chicago
Zhejiang University
Jiangsu Cancer Institute & Hospital
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Aristotle University Of Thessaloniki
Unity Health Toronto
The First Affiliated Hospital of Soochow University
University Health Network, Toronto
Onconic Therapeutics Inc.
Taipei Veterans General Hospital, Taiwan
Tongji Hospital
Second Life Therapeutics
Yonsei University
Gustave Roussy, Cancer Campus, Grand Paris
Ospedale Santa Croce-Carle Cuneo
Seoul National University Hospital
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
GE Healthcare
Fudan University
Centre Leon Berard
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
NHS Grampian
Beijing Biostar Pharmaceuticals Co., Ltd.
Shanghai Gynecologic Oncology Group
Oncare Madrid
Seoul National University Hospital
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Tongji Hospital
Tongji Hospital
GlaxoSmithKline
University of South Florida